That Was The Year That Was: Scrip's Biggest Stories Of 2015
This article was originally published in Scrip
As the effects of too much seasonal feasting begin to fade, what better way to kick back and relax than with a quick review of the year? For your delectation, Scrip has surveyed the stats to see which stories kept our readers clicking in 2015:
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.